Oragenics Files 8-K on Shareholder Nominations & Financials
Ticker: OGEN · Form: 8-K · Filed: Feb 18, 2025 · CIK: 1174940
Sentiment: neutral
Topics: shareholder-nominations, financials, regulatory-filing
TL;DR
Oragenics filed an 8-K for shareholder nominations and financials. Keep an eye on leadership changes.
AI Summary
Oragenics, Inc. filed an 8-K on February 18, 2025, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11 and including financial statements and exhibits. The filing date for this report is February 18, 2025, with the earliest event reported on February 17, 2025. The company is incorporated in Florida and its principal executive offices are located in Sarasota, FL.
Why It Matters
This filing indicates potential changes or discussions regarding company leadership and provides updated financial information, which could impact investor decisions.
Risk Assessment
Risk Level: low — This is a routine filing for an 8-K, primarily reporting on shareholder nominations and financial statements, without immediate significant financial events.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- Exchange Act Rule 14a-11 (legal_document) — Regulation for shareholder nominations
- February 17, 2025 (date) — Date of earliest event reported
- February 18, 2025 (date) — Date of report
- Florida (location) — State of incorporation
- Sarasota, FL (location) — Principal executive offices
FAQ
What specific shareholder nominations are being reported in this 8-K?
The filing states 'Shareholder Nominations Pursuant to Exchange Act Rule 14a-11' as an item information, but the specific details of the nominations are not provided in the excerpt.
What financial statements are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item information, but the specific financial statements are not detailed in the provided text.
When was the earliest event reported in this filing?
The earliest event reported was on February 17, 2025.
What is Oragenics, Inc.'s principal executive office address?
The principal executive offices are located at 1990 Main Street, Suite 750, Sarasota, FL 34236.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 18, 2025 regarding ORAGENICS INC (OGEN).